Internal Funding Opportunities
The following are calls for internal funding opportunities within the Temerty Faculty of Medicine.
Pathway Grant - Deadline for abstracts: March 4, 2021
To address the gap between the Temerty Faculty of Medicine’s Project Grant proposals and CIHR’s limited available funding envelope, the OVDRI has launched a Pathway Grant for the Fall 2020 Project Grant competition. This funding program functions as an internal CIHR bridge grant for top-rated Project Grant proposals from on-campus Temerty Faculty of Medicine applicants:
Up to 3 grants per Project competition (Spring and Fall)
$100,000 for 1 year, w/potential 1-year no-cost extension
Top 3 unfunded proposals, by percentile rank within review committee, will receive Pathway Grants
Terms & Conditions:
To be eligible for a Pathway Grant – you must be enrolled and in good standing with the Temerty Faculty of Medicine's College of Internal Scientific Reviewers at the time of the prior Project Grant competition. To be in good standing, you simply have to remain available to serve as an internal reviewer should you be selected to do so by the College for a specific grant.
Expense eligibility follows the Tri-Council policy on financial management
Temerty Knowledge Translation Grant: Development of Novel Antibody Tools for COVID-19 Diagnosis or Immunotherapies - Deadline for submission: February 15, 2021
We are very pleased to announce the launch of the Temerty Knowledge Translation Grant focused in the priority area of: development of novel antibody tools for COVID-19 diagnosis or immunotherapies.
These grants are designed to support our researchers in translating fundamental science towards impactful applications in collaboration with a knowledge translation partner.
Value: three thresholds of $25,000, $50,000, and $100,000 per award
Duration: 1 year, with the possibility of an additional 1-year no-cost extension
Application deadline: February 15th
Eligibility: all Temerty Medicine faculty members can apply. A KT partner (e.g. clinical collaborator, industrial partner) must also be included.
Application form for further details and submission process.
Please note that this is the first in a series of Temerty Knowledge Translation Grants. Future calls will be open to any KT-oriented projects or focused on other emerging priority areas.
Temerty Innovation Grants for AI in Medicine - Deadline for submission: April 30, 2021
• Value: Up to $200,000 for granting period of up two years
• Number of grants available: 2 grants
• Duration: One year with a possibility of extension to two years
• Application Deadline: (***APPLICATION DEADLINE EXTENDED to April 30, 2021***)
• Application Procedure: Proposals are to be submitted using the PDF application form to the T-CAIREM Centre Administrator with the subject line: Temerty Innovation Grant Application.
• For more Information: Zoryana Salo, Centre Administrator
Full or Associate Professor – Temerty Health Innovation & Technology Chairs - Deadline for submission: April 30, 2021
The Temerty Faculty of Medicine seeks applicants for the inaugural Temerty Health Innovation & Technology Chair. Two positions are available. The successful candidate must already hold, or be eligible for, an academic appointment within the Temerty Faculty of Medicine, University of Toronto (U of T), at the rank of Associate or Full Professor. The term of the Chair position is 5 years with the opportunity for one 5-year renewal following a successful review. Applications will be accepted until April 30, 2021, or until filled. Position start date is July 1, 2021, or a mutually agreed upon date.
In the course of their activities, the Temerty Health Innovation & Technology Chair will support the development and implementation of strategies (research, clinical, industrial, and/or educational) that enable the success of new health-care technologies to emerge from the Faculty’s ecosystem. These strategies may range broadly across health application areas, including but not limited to: machine learning, advanced imaging, digital health, diagnostics, novel drug and/or biological therapies, rapid on-site manufacturing, personalized interventions, medical devices, etc. The Chair will support fellow innovators (faculty and/or trainees) on the practical and/or commercial implementation of their ideas during early stages of translational design work and concept development. Proposed innovations should have the potential for significant impact in clinic settings, the home, or the community, with a particular emphasis on scalability, a better quality of life, and/or reducing health inequities.
The successful candidate will also be appointed as a mentor actively engaged in the mission of the Health Innovation Hub (H2i), a campus-linked accelerator within the Temerty Faculty of Medicine whose mission statement is “to educate, enable, partner, and facilitate early-stage entrepreneurs in the commercialization of health matters.” A minimum of 20% of the Chair’s activity will be directly related to H2i’s mission. It is anticipated that these Temerty Health Innovation & Technology Chairs will be the first two of twelve Chairs in Health Nexus - a U of T research & education initiative that champions the successful outcome of health innovation.
Applicants from a wide range of backgrounds, who are widely respected in their field, are encouraged to apply. We welcome applicants working in any research domain, from basic to clinical to industrial research and hold either a PhD, MD or equivalent in an allied health area. Applicants must have a demonstrated track record of: peer-reviewed publications in main-stream journals, funding of collaborative research projects, successfully moving innovations towards new and improved health care practices; outstanding teaching performance and mentorship; interdisciplinary collaborations; communication skills; and inclusive leadership. The successful candidate will be a developer and promoter of entrepreneurial activity, with a proven ability to transform innovative ideas from discovery, research and/or de novo development into new technologies supporting improved health care practice or policy.
The Chair award will provide funding of $200,000 p.a. with a maximum of 75% to support the Chairholder’s salary and the remainder to directly support the Chair’s required activity costs in health innovation and technology and engaging with H2i. The Chair holder’s renumeration is expected to be commenserate with qualifications and experience.
Applications will be accepted until April 30, 2021, or until the position is filled. All nominations must be put forward by a Departmental Chair in the Temerty Faculty of Medicine. There is a limit of one application per department. Applications should include: a cover letter of support from the Chair confirming a 20% time commitment to H2i, the applicant’s curriculum vitae, and a 5-page (maximum) outline of current and future plans for innovation and/or technology advancement, education interests related to the Chair’s mandate, engagement with H2i, an EDI statement, and the names of three academic or industry references. Applications to be submitted as a single PDF and sent via email to:
Prof. Reinhart Reithmeier
Interim Vice Dean, Research & Innovation, Temerty Faculty of Medicine
c/o Cindy Faber
Research Services Officer, Office of the Vice Dean, Research & Innovation
Home to over 40 departments and institutes, the University of Toronto's Temerty Faculty of Medicine lies at the heart of the Toronto Academic Health Science Network (TAHSN) and is a global leader in groundbreaking research and education, spanning clinical medicine, basic science and the rehabilitation
For more information about the Temerty Faculty of Medicine’s research & innovation platform, please visit: medicine.utoronto.ca/research
The Health Innovation Hub was established to create a culture, infrastructure, and momentum that translates discoveries and ideas into problem-solving designs, services and products, and to foster the success of health technology companies.
For more information about H2i, please visit: h2i.utoronto.ca
Also see the Faculty’s Academic Strategic Plan for further details on its institutional vision: medicine.utoronto.ca/asp
The University of Toronto is strongly committed to diversity within its community and especially where possible welcomes nominations from racialized persons / persons of colour, women, Indigenous / Aboriginal People of North America, persons with disabilities, LGBTQ persons, and others who may contribute to the further diversification of ideas.
All qualified candidates are encouraged to apply; however, Canadians and permanent residents will be given priority.
EMHSeed Funding - Deadline for submission: March 31, 2021
Expanding research impact through inter-disciplinary collaboration
The Joint EMHSeed and XSeed is an interdivisional research funding program designed to promote multi-disciplinary research and catalyze new innovative partnerships between a coPI from the Faculty of Applied Science and Engineering (FASE) and a coPI from outside Engineering. Partner divisions for these programs are:
For EMHSeed: Faculty of Medicine (FoM), UofT Affiliated Hospitals, Medicine by Design (MbD), Translational Biology and Engineering Program (TBEP)
For XSeed: Faculty of Arts and Science (FAS), University of Toronto Mississauga (UTM), University of Toronto Scarborough (UTSC), Dalla Lana School of Public Health (DLSPH), as well as other UofT Divisions.
Funding is available for a maximum of fifteen (15) new collaborative projects beginning in early September 2020.
The budget for each Seed project will be $60,000 CAD/year for two (2) years. In exceptional cases, a no-cost extension for an additional year will be considered. The $60,000 CAD/year amount for each project is the sum of total cash invested by each of the participating Faculties and departments/institutes,
Each coPI should be eligible to hold, as PI, tri-council agency grants (NSERC, CIHR, or SSHRC).
One PI should have a primary appointment with an Engineering unit, and one PI should have his/her primary appointment outside Engineering.
A PI can hold a maximum of one EMHSeed and one XSeed funded project at any point in time.
EMHSeed funding is for faculty members that have an appointment status at FoM and UofT Affliated Hospitals; XSeed is for faculty members with appointment status at FAS, UTM, UTSC, DLSPH and other divisions.
Deadline for documentation: March 31, 2021 at 12:00 noon.
McLaughlin Centre 2021 Accelerator Grants - Deadline for LOIs: December 9, 2020
LOI Deadline: December 4, 2020
LOI Decision: January 8, 2021
Application Deadline: March 5, 2021
Application Decision: April 23, 2021
Funding Start: May 1st, 2021 *LOI form at: www.mclaughlin.utoronto.ca
The McLaughlin Centre is pleased to announce its 11th research funding competition. The competition will be based on invited grant applications passing an initial letter of intent stage. Both steps will go through committee peer-review adjudicated by the Director. Letters of Intent up to two pages long should outline (i) background and rationale, (ii) objectives and activities, (iii) relevance to the McLaughlin Centre mission, (iv) planned deliverables and (v) a brief budget summary. Full grant applications will be a maximum of 10 pagesincluding references. Priority will be given to applications demonstrating promise for near-term deliverables, potential to seed larger grants, and those involving two or more institutions from the University of Toronto Faculties (and their Departments and Institutes) and the hospitals/research institutes fully affiliated with the University of Toronto (TAHSN). Successful grants will be awarded for one year with up to $100,000 from the McLaughlin Centre. A requirement is that the McLaughlin Centre investment be equally leveraged with other funds necessary for the completion of the project. (Note: considering other funding opportunities in Toronto, if your project involves cancer or COVID-19 please contact us in advance. We also prefer one application per Principal Investigator). The emphasis in this Call will be Genomic Data Generation and Integration for Discovery: 1. Building clinical and control genome-wide datasets. The emphasis this year will be projects for long-read genome sequencing, RNAseq, and epigenomics datasets for discovery and, 2. Importing genomic data from other databases (e.g. UK Biobank) and integrating/analyzing with local data, as well as linking whole genome datasets with health and administrative databases. Developing integrated analysis pipelines and databases for discovery will also be considered.
MITO2i - Innovation Grants - Deadline for submission: September 14, 2020
The MITO2i Innovation Grants are meant to fund impactful projects that brings novel ways to transform mitochondrial health and be able to have a direct impact on the quality of life of patients with mitochondrial disease or dysfunction. The objective of the Innovation grants is to generate new knowledge, promoting innovation and interdisciplinary research. MITO2i will invest in bold interdisciplinary ideas, ranging from basic (e.g. fundamental biological concepts) to clinical and translational research (diagnostic and novel treatments for mitochondrial dysfunction) and health policy, economics, law and ethics and epidemiology, to cultivate new concepts that are expected to be of critical importance to mitochondrial medicine and research.
Research areas can include but not limited: 1) research in all disease and clinical applications in which mitochondrial mutations, defects and/or dysfunction may play a role in the pathogenesis of disease, 2) development of novel compounds that improve mitochondrial function and therapeutic treatments such as mitochondrial transplant, mitochondrial augmentation therapy, precision nutrition and others, 3) development of diagnostic tools and technologies for detection of mitochondria defects, 4) projects concerning the law, ethics, patient counselling, health policy and economics and epidemiology of mitochondrial medicine research.
Successful grants will be awarded up to $100,000 for a two-year project.
Each application should be representing two distinct disciplines (by NPI and Co-PI) in a collaboration to develop an interdisciplinary project that advances the innovation mission for mitochondria medicine and research.
NPI’s and Co-PI’s from any academic and/or hospital institutions may apply. Researchers can only be NPI and Co-PI in one application; however, they can be listed as collaborators in more than one application.
MITO2i investment should be equally matched (cash and/or in-kind) with other funds to demonstrate commitment to the project. This can include other grant funding, institutional contributions, external investments, and others.
It is strongly advised that applicants consider, and plan for, engaging with people affected by mitochondrial disease and/or other chronic diseases affected by mitochondrial dysfunction. This could include patient, patient advocates, foundations, organizations, and patient groups. This element should be integral to the design of the proposed research.